ValiRx PLC | Balance Sheet

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
960.30
452.80
1,695.50
701.40
845.20
372.90
Total Accounts Receivable
463.30
620.20
629.60
1,366.90
1,164.00
609.40
Inventories
4.10
11.20
44.00
-
-
-
Other Current Assets
27.10
142.70
56.80
58.60
-
25.90
Total Current Assets
1,454.70
1,226.90
2,425.80
2,126.90
2,009.20
1,008.20
Net Property, Plant & Equipment
0.70
1.50
22.20
10.60
-
-
Total Investments and Advances
768.30
-
-
-
-
-
Long-Term Note Receivable
-
14.60
-
-
-
-
Intangible Assets
1,882.80
2,380.00
2,673.40
2,824.60
2,927.80
3,226.50
Total Assets
4,106.50
3,623.10
5,121.40
4,962.00
4,937.00
4,234.60
ST Debt & Current Portion LT Debt
-
-
-
1,294.30
390.10
Accounts Payable
742.80
514.20
-
-
-
Other Current Liabilities
133.30
320.90
588.50
1,298.30
1,394.30
Total Current Liabilities
876.10
835.10
588.50
2,592.60
1,784.40
Total Liabilities
876.10
835.10
588.50
2,592.60
1,784.40
Common Equity (Total)
1,110.00
1,578.80
4,453.80
2,349.80
3,177.40
Total Shareholders' Equity
3,230.40
2,761.70
4,453.80
2,349.80
3,177.40
Total Equity
3,230.40
2,788.00
4,532.80
2,369.50
3,152.60
Liabilities & Shareholders' Equity
4,106.50
3,623.10
5,121.40
4,962.00
4,937.00
Accumulated Minority Interest
-
26.40
79.10
19.60
24.70
Preferred Stock (Carrying Value)
4,340.40
4,340.40
-
-
-

About ValiRx

View Profile
Address
16 Upper Woburn Place
London Greater London WC1H 0BS
United Kingdom
Employees -
Website http://www.valirx.com
Updated 07/08/2019
ValiRx Plc operates as a biopharmaceutical company which engages in the development of novel technologies and products in oncology therapeutics and diagnostics. The company products focuses on the epigenomic analysis and treatment of cancer, as well as the technologies can be also applied in other fields, such as neurology and inflammatory diseases. It operates through the Drug Development and Sale of Self-Test Drug Kits segments.